Genmab A/S has announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the investigational medicine epcoritamab (DuoBody®-CD3xCD20) to treat follicular lymphoma (FL). FL is usually a slow-growing or indolent form of non-Hodgkin’s lymphoma (NHL) arising from B-lymphocytes, and it is the second most common form of NHL globally. FL is incurable with conventional therapy for patients who relapse or become refractory, making additional options for treatment needed. Epcoritamab, an investigational IgG1-bispecific antibody, is created using Genmab’s proprietary DuoBody-CD3 technology, which is designed to direct cytotoxic T cells selectively to tumors to evoke an immune response towards malignant cells. Epcoritamab binds simultaneously to CD3 on T cells and CD20 on B cells and induces T cell mediated killing of lymphoma B cells. Genmab is an international biotechnology company with a core mission to improve the lives of people with cancer and to transform cancer treatment.

Read more here.